Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$1.17 +1.8%	$0.99	$0.69 ▼ $3.94	$231.89M	0.7	4.83 million shs	2.32 million shs
EVLO Evelo Biosciences	$0.00	$0.00	$0.00 ▼ $0.02	$9K	0.79	13,056 shs	1 shs
FHTX Foghorn Therapeutics	$5.16 +4.2%	$4.43	$2.94 ▼ $10.25	$285.95M	3.05	143,021 shs	80,445 shs
GRAY Graybug Vision	$1.61 +1.9%	$1.74	$5.00 ▼ $22.12	$2.53M	1.2	2,165 shs	21,507 shs
VBIV VBI Vaccines		$0.23	$0.06 ▼ $1.35	$1.87M	2.18	3.66 million shs	29.90 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	0.00%	+17.85%	+4.55%	-4.80%	-50.38%
EVLO Evelo Biosciences	0.00%	0.00%	0.00%	0.00%	+150.00%
FHTX Foghorn Therapeutics	0.00%	+6.61%	+22.86%	+50.00%	-8.19%
GRAY Graybug Vision	+1.90%	+2.55%	-1.23%	-11.54%	-62.21%
VBIV VBI Vaccines	0.00%	0.00%	0.00%	0.00%	-91.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	4.1378 of 5 stars	3.4	3.0	0.0	3.9	2.0	1.7	0.6
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	1.8296 of 5 stars	3.6	0.0	0.0	0.0	2.0	1.7	0.6
GRAY Graybug Vision	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	497.78% Upside
EVLO Evelo Biosciences	0.00	N/A	N/A	N/A
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	134.98% Upside
GRAY Graybug Vision	0.00	N/A	N/A	N/A
VBIV VBI Vaccines	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ESPR, EVLO, GRAY, FHTX, and VBIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/23/2025	FHTX Foghorn Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Mkt Outperform	$9.00
4/23/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Outperform	$9.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	0.70	$0.02 per share	48.70	($1.97) per share	-0.59
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	$22.60M	12.73	N/A	N/A	($0.82) per share	-6.29
GRAY Graybug Vision	N/A	N/A	N/A	N/A	$1.67 per share	N/A
VBIV VBI Vaccines	$9.41M	0.00	N/A	N/A	$0.32 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.80	0.00	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
EVLO Evelo Biosciences	-$114.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	7/7/2025 (Estimated)
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	0.00	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
GRAY Graybug Vision	-$35.60M	-$24.23	N/A	N/A	N/A	N/A	-77.61%	-71.34%	N/A
VBIV VBI Vaccines	-$92.84M	N/A	0.00	N/A	N/A	-881.79%	-525.42%	-45.87%	N/A

Latest ESPR, EVLO, GRAY, FHTX, and VBIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
EVLO Evelo Biosciences	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
GRAY Graybug Vision	N/A	N/A	N/A	N/A	N/A
VBIV VBI Vaccines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.18	0.81
EVLO Evelo Biosciences	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	3.16	3.16
GRAY Graybug Vision	N/A	10.73	10.72
VBIV VBI Vaccines	N/A	0.34	0.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
EVLO Evelo Biosciences	0.31%
FHTX Foghorn Therapeutics	61.55%
GRAY Graybug Vision	49.94%
VBIV VBI Vaccines	12.26%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
EVLO Evelo Biosciences	1.02%
FHTX Foghorn Therapeutics	7.58%
GRAY Graybug Vision	7.94%
VBIV VBI Vaccines	10.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
EVLO Evelo Biosciences	120	18.98 million	18.79 million	No Data
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
GRAY Graybug Vision	27	1.57 million	20.25 million	Not Optionable
VBIV VBI Vaccines	22	28.68 million	25.71 million	Optionable

ESPR, EVLO, GRAY, FHTX, and VBIV Headlines

Recent News About These Companies

Brii Biosciences buying VBI Vaccine’s hepatitis B therapy

January 24, 2025 | ncbiotech.orgN

VBI Vaccines Restructures and Acquired by K2 VBI Trust

January 3, 2025 | tipranks.com

VBI recalls PreHevbrio and winds down operations

November 20, 2024 | thepharmaletter.comT

Hepatitis B Vaccine PreHevbrio Recalled Due to Company Bankruptcy

November 19, 2024 | empr.comE

VBI Vaccines recalls hepatitis B shot as it winds down operations

November 18, 2024 | fiercepharma.comF

VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations

November 15, 2024 | businesswire.com

VBI Vaccines Inc. (VBIV): Unpacking the 80% Stock Surge During Restructuring

August 6, 2024 | bovnews.comB

Why Is VBI Vaccines (VBIV) Stock Up 62% Today?

August 6, 2024 | investorplace.com

VBI Vaccines to be delisted from Nasdaq following restructuring

August 4, 2024 | investing.com

VBI Vaccines Provides an Update on its Restructuring Proceedings

August 3, 2024 | finance.yahoo.com

VBI Vaccines secures court protection for restructuring

August 1, 2024 | investing.com

VBI craters as investors react to Hep B vaccine data

July 31, 2024 | pharmaphorum.comP

VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

July 30, 2024 | stockhouse.com

VBI Vaccines Announces Results of Annual General Meeting

June 25, 2024 | businesswire.com

VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients

May 29, 2024 | businesswire.com

VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients

May 22, 2024 | businesswire.com

VBIV Stock Earnings: VBI Vaccines Misses EPS, Misses Revenue for Q1 2024

May 15, 2024 | investorplace.com

VBI Vaccines Reports First Quarter 2024 Financial Results

May 15, 2024 | businesswire.com

VBI Vaccines expands partnership with Canadian government on a vaccine platform

May 13, 2024 | plant.caP

VBI Vaccines Reports Full Year 2023 Financial Results

April 16, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESPR, EVLO, GRAY, FHTX, and VBIV Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$1.17 +0.02 (+1.83%)

Closing price 07/3/2025 03:42 PM Eastern

Extended Trading

$1.16 -0.01 (-0.51%)

As of 07/3/2025 04:47 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Evelo Biosciences NASDAQ:EVLO

$0.0005 0.00 (0.00%)

As of 07/3/2025

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics NASDAQ:FHTX

$5.16 +0.21 (+4.24%)

As of 07/3/2025 01:04 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Graybug Vision NASDAQ:GRAY

$1.61 +0.03 (+1.90%)

As of 07/3/2025

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.

VBI Vaccines NASDAQ:VBIV

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time